2019
A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors
Gaillard SL, Zahurak M, Sharma A, Durham J, Reiss K, Sartorius‐Mergenthaler S, Downs M, Anders N, Ahuja N, Rudek M, Azad N. A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. Cancer 2019, 125: 2837-2845. PMID: 31012962, PMCID: PMC6663621, DOI: 10.1002/cncr.32138.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAged, 80 and overAnorexiaAntineoplastic Combined Chemotherapy ProtocolsAzacitidineDepsipeptidesDNA Modification MethylasesDrug Administration ScheduleFemaleHistone Deacetylase InhibitorsHumansLong Interspersed Nucleotide ElementsMaleMaximum Tolerated DoseMethyltransferasesMiddle AgedNauseaNeoplasmsConceptsHistone deacetylase inhibitor romidepsinDisease control rateAdvanced solid tumorsPhase 1 studyCC-486Solid tumorsDose-escalation portionPhase 2 doseDose-limiting toxicityPossible clinical benefitPhase 1 trialDose-escalation designElement-1 methylationLINE-1 methylationStable diseaseCommon toxicitiesDose expansionExpansion cohortPrimary outcomeClinical benefitControl rateDrug exposureBlood samplesDay 1Dose levels
2007
The role of radiation in retroperitoneal sarcomas: a surgical perspective
Pawlik TM, Ahuja N, Herman JM. The role of radiation in retroperitoneal sarcomas: a surgical perspective. Current Opinion In Oncology 2007, 19: 359-366. PMID: 17545800, DOI: 10.1097/cco.0b013e328122d757.Peer-Reviewed Original ResearchConceptsExternal beam radiation therapyBeam radiation therapyIntraoperative radiation therapyLocal recurrence rateRadiation therapyRetroperitoneal sarcomaRecurrence rateAdjuvant external beam radiation therapyLocal recurrence-free survivalPreoperative external beam radiation therapyRadiation-related morbidityRetroperitoneal sarcoma patientsLocal control rateLocal-regional controlPreoperative radiation therapyRecurrence-free survivalTiming of administrationSurgical patientsTumor resectabilitySarcoma patientsTechniques of deliveryControl rateSurgical perspectiveAdditional toxicityRecent studies